Sonnet biotherapeutics announces clinical trial of son-1010 in healthy volunteers

Represents sonnet's second clinical trial with son-1010 study expected to provide important pk and pd data for potential additional indications of interest recruitment initiated with dosing anticipated to begin imminently princeton, nj / accesswire / july 21, 2022 / sonnet biotherapeutics holdings, inc., (nasdaq:sonn) a clinical-stage company developing targeted immunotherapeutic drugs, announced today that a second phase 1 clinical trial of son-1010(il12-fhab) has been authorized to begin, based on the successful initiation of the first two cohorts in the first-in-human (fih) dose-escalation trial (sb101) in patients with advanced solid tumors (nct05352750). this new study (sb102), being conducted in healthy volunteers in australia, is a single ascending dose-escalation (sad) trial designed to provide extensive additional pharmacokinetic (pk), pharmacodynamic (pd) and cell response data with son-1010 (nct05408572).
SONN Ratings Summary
SONN Quant Ranking